- Home
- HRMY vs RPD Comparison
HRMY vs RPD Comparison
Compare HRMY & RPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- RPD
- Stock Information
- Founded
- HRMY 2017
- RPD 2000
- Country
- HRMY United States
- RPD United States
- Employees
- HRMY N/A
- RPD N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- RPD Computer Software: Prepackaged Software
- Sector
- HRMY Health Care
- RPD Technology
- Exchange
- HRMY Nasdaq
- RPD Nasdaq
- Market Cap
- HRMY 1.8B
- RPD 1.5B
- IPO Year
- HRMY 2020
- RPD 2015
- Fundamental
- Price
- HRMY $34.00
- RPD $23.40
- Analyst Decision
- HRMY Strong Buy
- RPD Hold
- Analyst Count
- HRMY 9
- RPD 19
- Target Price
- HRMY $54.44
- RPD $32.94
- AVG Volume (30 Days)
- HRMY 642.5K
- RPD 872.3K
- Earning Date
- HRMY 08-05-2025
- RPD 08-07-2025
- Dividend Yield
- HRMY N/A
- RPD N/A
- EPS Growth
- HRMY 13.13
- RPD N/A
- EPS
- HRMY 2.62
- RPD 0.41
- Revenue
- HRMY $744,852,000.00
- RPD $849,159,000.00
- Revenue This Year
- HRMY $20.10
- RPD $2.81
- Revenue Next Year
- HRMY $18.01
- RPD $4.05
- P/E Ratio
- HRMY $13.10
- RPD $56.57
- Revenue Growth
- HRMY 20.62
- RPD 6.19
- 52 Week Low
- HRMY $26.47
- RPD $21.61
- 52 Week High
- HRMY $41.61
- RPD $44.48
- Technical
- Relative Strength Index (RSI)
- HRMY 58.91
- RPD 46.92
- Support Level
- HRMY $31.70
- RPD $23.83
- Resistance Level
- HRMY $35.08
- RPD $25.85
- Average True Range (ATR)
- HRMY 0.95
- RPD 0.90
- MACD
- HRMY 0.27
- RPD 0.08
- Stochastic Oscillator
- HRMY 71.80
- RPD 25.53
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About RPD Rapid7 Inc.
Founded in 2000, Rapid7 is a cybersecurity company that began providing vulnerability management solutions. It has, however, expanded its portfolio to provide extended detection and response; security information and event management; cloud security, threat intelligence, and application security; and security orchestration, automation, and response. The Boston-based company went public in 2015.